Study: BIRC2 overexpression could be a key marker for immunotherapy resistance

Study: BIRC2 overexpression could be a key marker for immunotherapy resistance

Study: BIRC2 overexpression could be a key marker for immunotherapy resistance

Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell's natural "suicide" signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer.